About the Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD) Working Group

Interstitial lung diseases (ILD), including those related to connective tissue disease (CTD), and idiopathic pulmonary fibrosis (IPF) carry high morbidity and mortality.

Great efforts are under way to develop and investigate meaningful treatments in the context of clinical trials. However, efforts have been challenged by a lack of validated outcome measures and by inconsistent use of measures in clinical trials.

Khanna Headshot

Dinesh Khanna



Sydney Montesi



susanna proudman

Susanna Proudman


Simon Walsh


Athol Wells


david roofeh

David Roofeh


Jesudasen, Sirus Jonathan

Sirus Jesudasen


Technical Advisory Group Instrument Townhall Presentation from the CTD-ILD group of their Instruments for Lung Physiology

OMERACT Endorsed Core Domain Set Clinical Trials in Connective Tissue Disease - Interstitial Lung Disease (CTD-ILD)

ctd ild core set


Working Group Members:

Alicia Hinze
Alireza Meysami
Angie Botto-van Bemden
Anupam Wakhlu
Athol Wells
Aya Akmal Amin
Chris Denton
Corrado Campochiaro
David Roofeh
Didem Saygin
Dinesh Khanna
Eduardo Dourado
Ellen Romich
Eric Matteson
Fernando Martinez
Gabriela Tabaj
Gary Choque
George Wells
Ghaydaa Dabie
Ilfita Sahbudin
James Seibold
Jeff Swirgis
Joanna Porter
John Pauling
Kevin Brown
Khaled Abdelgalil
Kyung Min Ko

Lesley Ann Saketoo
Marta Moura
Maxine Isbel
Nicola Dalbeth
Nino Tsiskarishvili
Peter Tugwell
Philippe Dieude
Priya Agarwala
Puja Mehta
Rachana Krishna
Raouf Hajji
Rohit Aggarwal
Rositsa Karalilova
Sasikala Bheemireddy
Shaney Barratt
Shawna Grosskleg
Shikha Mittoo
Simon Walsh
Sirus Jesudasen
Sonali Narain
Souhil Zaim
Susanna Proudman
Sydney Montesi
Tamer Gheita
Teodora Serban
Toby Maher
Vibeke Strand

Interested in joining the working group as a member?

We are excited to invite you to join the OMERACT mailing list! This will ensure you stay updated on our latest news and activities.
In addition to joining our mailing list, we also encourage you to become part of our active Working Groups. Being part of these groups is an opportunity to collaborate with experts in the field, contribute to important discussions, and influence the future direction of rheumatology outcomes research.
We look forward to your valuable contributions and active participation in our community.


* indicates required
Working Groups
Scroll to Top